Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases.

Cancer Biol Med · 2015 · PMC4493380 · PMID 26175927

Europe PMC DOI

hedged sentence

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

marginally significantP =0.071so close (0.05 < p ≤ 0.1)

However, stratified analysis indicated that the PFS of patients with stages III and IV CSCLC showed marginally significant difference between the TEP/TCE and EP/CE groups (19.5 vs . 7.6 months; P =0.071).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.